A Study of the Safety and Effectiveness of Infliximab (Remicade) in Patients With Giant Cell Arteritis

• Status: Terminated
• Trial end date: 2005-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the safety and efficacy (effectiveness) of Infliximab (Remicade) in patients with Giant Cell Arteritis. Infliximab (Remicade) targets specific proteins in the body's immune system to help control the development of inflammation to help reduce painful disease.

• Phase: Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Centocor, Inc.
• Collaborator: The Cleveland Clinic
• Treatments: Infliximab

Criteria

Inclusion Criteria:

• Patients who have a diagnosis of Giant Cell Arteritis (GCA)

• Patients who have a diagnosis of GCA of = 4 weeks' duration

• Patients who are receiving = 40 mg/day of prednisone/prednisolone Exclusion Criteria:

• Patients must not have a prior diagnosis of GCA > 4 weeks

• Patients must not have failed to respond to glucocorticosteroid therapy within 5 days of initiation of therapy.